BioCentury | Oct 17, 2005
Strategy

Vaccines getting hot

...went into receivership in February 2004 after failing to raise cash from its Canadian parent, Qbiogene Inc....
BioCentury | Jan 6, 2003
Finance

Ebb & Flow

...include NMT's investments in Swiss anti-infectives business Arpida , Canadian research tool and product provider Qbiogene...
BioCentury | Aug 12, 2002
Company News

Kreatech Biotechnology B.V., Qbiogene sales and marketing update

...The companies expanded their 2000 deal for Qbiogene to market fluorescence in situ hybridization kits that...
...situ hybridization kits that use Universal Linkage System (ULS) labeling probes from Kreatech. As expanded, Qbiogene...
...companies will jointly develop molecular cytogenetics research tools. Kreatech Biotechnology B.V. , Amsterdam, the Netherlands Qbiogene Inc....
BioCentury | Feb 26, 2001
Company News

Epoch Biosciences management update

...president; and Merl Hoekstra as VP of corporate development, formerly CSO and general manager at Qbiogene Inc. WIR...
BioCentury | Jan 9, 2001
Financial News

Qbiogene raises $20 million

...Medical Technologies; PolyTechnos Venture-Partners; Schweizerische Gesellschaft fur Aktienhandel & Research; and Bio World Venture Capital. Qbiogene...
BioCentury | Aug 14, 2000
Company News

Qbiogene, Glaxo Wellcome deal

...for research use, obtained a license to develop GLXO’s Admid System for generating recombinant adenoviruses. Qbiogene...
...target discovery and gene therapy. Qbiogene also markets its AdenoQuest and AdEasy adenovirus production systems. Qbiogene Inc....
BioCentury | Aug 9, 2000
Company News

Qbiogene to develop Glaxo's adenovirus technology

...the Admid System, a technology developed by Glaxo Wellcome (LSE:GLXO; GLX) to generate recombinant adenoviruses. Qbiogene...
...further the development of the technology for use in drug target discovery and gene therapy. Qbiogene...
Items per page:
1 - 7 of 7
BioCentury | Oct 17, 2005
Strategy

Vaccines getting hot

...went into receivership in February 2004 after failing to raise cash from its Canadian parent, Qbiogene Inc....
BioCentury | Jan 6, 2003
Finance

Ebb & Flow

...include NMT's investments in Swiss anti-infectives business Arpida , Canadian research tool and product provider Qbiogene...
BioCentury | Aug 12, 2002
Company News

Kreatech Biotechnology B.V., Qbiogene sales and marketing update

...The companies expanded their 2000 deal for Qbiogene to market fluorescence in situ hybridization kits that...
...situ hybridization kits that use Universal Linkage System (ULS) labeling probes from Kreatech. As expanded, Qbiogene...
...companies will jointly develop molecular cytogenetics research tools. Kreatech Biotechnology B.V. , Amsterdam, the Netherlands Qbiogene Inc....
BioCentury | Feb 26, 2001
Company News

Epoch Biosciences management update

...president; and Merl Hoekstra as VP of corporate development, formerly CSO and general manager at Qbiogene Inc. WIR...
BioCentury | Jan 9, 2001
Financial News

Qbiogene raises $20 million

...Medical Technologies; PolyTechnos Venture-Partners; Schweizerische Gesellschaft fur Aktienhandel & Research; and Bio World Venture Capital. Qbiogene...
BioCentury | Aug 14, 2000
Company News

Qbiogene, Glaxo Wellcome deal

...for research use, obtained a license to develop GLXO’s Admid System for generating recombinant adenoviruses. Qbiogene...
...target discovery and gene therapy. Qbiogene also markets its AdenoQuest and AdEasy adenovirus production systems. Qbiogene Inc....
BioCentury | Aug 9, 2000
Company News

Qbiogene to develop Glaxo's adenovirus technology

...the Admid System, a technology developed by Glaxo Wellcome (LSE:GLXO; GLX) to generate recombinant adenoviruses. Qbiogene...
...further the development of the technology for use in drug target discovery and gene therapy. Qbiogene...
Items per page:
1 - 7 of 7